Story

Ambu Stock Plunges After Company Cuts Full-Year Revenue Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20261 min read
Ambu Stock Plunges After Company Cuts Full-Year Revenue Guidance
Text size
Background

Shares of Ambu A/S (AMBUb) plunged 16.2% on Wednesday after the medical device company lowered its full-year revenue outlook and posted disappointing fiscal third-quarter results, citing weakness in the U.S. market.

Guidance Cut and Earnings Miss

Ambu announced it was reducing its full-year organic revenue growth forecast to approximately 10%, down from its previous range of 10–12%. The revision was driven by a significant slowdown in its Anesthesia & Patient Monitoring division, which is now expected to deliver only very low-single-digit organic growth for the year.

The company attributed the weakness to softer-than-anticipated sales volumes from customers in the United States. While its Endoscopy Solutions segment continued to perform steadily, it was not enough to offset the downturn in the anesthesia business.

The guidance cut accompanied a third-quarter earnings report that fell short of market expectations:

Sample IUX Markets – In-articleAd
  • Revenue: Came in at DKK 1.57 billion, missing the consensus estimate of DKK 1.62 billion.
  • Earnings Per Share (EPS): Was reported to be well below analyst forecasts.
  • Margins: Contracted sharply compared to the previous year, which the company linked to elevated expenses.

Market Reaction and Context

The dual impact of an earnings miss and a downward guidance revision sent the stock to DKK 65.7, moving it closer to its 52-week low of DKK 56.3. According to Investing.com, the sharp sell-off reflects a severe repricing of growth expectations by the market.

Investor concerns were amplified by an increasingly competitive environment. Key rivals, including Boston Scientific and Olympus, have been expanding their own single-use device portfolios, intensifying pressure in Ambu's core markets. Analysts at AL Sydbank had reportedly warned ahead of the release that a disappointing report could trigger significant volatility.

Read next

More on Stocks
Back to latest news

LATEST